Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tukysa | tucatinib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete | ||
Dojolvi | triheptanoin | Long-chain fatty acid oxidation disorders | Reimburse with clinical criteria and/or conditions | Complete | ||
Lonsurf | Trifluridine-Tipiracil | Gastric Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lonsurf | Trifluridine and Tipiracil | mCRC Resubmission | Do not reimburse | Complete | ||
Lonsurf | Trifluridine and Tipiracil | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
Lonsurf | trifluridine and tipiracil | Metastatic colorectal cancer | Reimburse with clinical criteria and/or conditions | Active | ||
MAR-Trientine | Trientine Hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Waymade-Trientine | trientine hydrochloride | Wilson's Disease | Reimburse with clinical criteria and/or conditions | Complete |